Opexa Therapeutics Inc. (OPXA: Quote) announced Tuesday that it entered into an agreement with Merck Serono, for the development and commercialization of Tcelna, a potential first-in-class personalized T-cell therapy for patients with multiple sclerosis.
Opexa Therapeutics gapped open sharply higher Tuesday, but then declined until around midday. The stock ended the day higher by 1.94 at $3.15 on the highest volume of the year. Opexa Therapeutics leaped to a 3 1/2 month high and re-crossed its 50 and 200-day moving averages.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org